• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM 0.00% 42.0¢

IMMUTEP LIMITED - Announcements

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Announcements


IMM Positive initial data in phase 2 Soft Tissue Sarcoma trialPRICE SENSITIVE02/05/24 download Created with Sketch. 200.6KB
IMM Immutep Quarterly Activities Report and Appendix 4CPRICE SENSITIVE29/04/24 download Created with Sketch. 499.37KB
IMM Positive preliminary topline results from TACTI-003 Cohort BPRICE SENSITIVE24/04/24 download Created with Sketch. 241.01KB
IMM CHDR to conduct first-in-human phase 1 trial of IMP761PRICE SENSITIVE18/04/24 download Created with Sketch. 299.16KB
IMM Positive Feedback received from Spanish Medicines Agency17/04/24 download Created with Sketch. 173.58KB
IMM Ceasing to be a substantial holder11/04/24 download Created with Sketch. 671.48KB
IMM Ceasing to be a substantial holder08/03/24 download Created with Sketch. 42.52KB
IMM First Clinical Data announced from 90mg Dosing of EftiPRICE SENSITIVE05/03/24 download Created with Sketch. 253.51KB
IMM Half Yearly Report and AccountsPRICE SENSITIVE28/02/24 download Created with Sketch. 2.01MB
IMM Becoming a substantial holder26/02/24 download Created with Sketch. 170.17KB
IMM Change in substantial holding22/02/24 download Created with Sketch. 675.37KB
IMM Immutep Investor Update21/02/24 download Created with Sketch. 1.43MB
IMM Change in substantial holding20/02/24 download Created with Sketch. 88.53KB
IMM Becoming a substantial holder15/02/24 download Created with Sketch. 90.89KB
IMM Ceasing to be a substantial holder14/02/24 download Created with Sketch. 155.43KB
IMM Appendix 3X - Anne Anderson14/02/24 download Created with Sketch. 169.25KB
IMM Appointment of Non-Executive Director14/02/24 download Created with Sketch. 176.94KB
IMM Notification regarding unquoted securities - IMM31/01/24 download Created with Sketch. 26.69KB
IMM Immutep Quarterly Activities Report and Appendix 4CPRICE SENSITIVE30/01/24 download Created with Sketch. 542.91KB
IMM Change in substantial holding15/01/24 download Created with Sketch. 683.83KB
IMM Immutep Corporate Presentation08/01/24 download Created with Sketch. 5.32MB
IMM First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial04/01/24 download Created with Sketch. 176.39KB
IMM Change of Registered Office Address22/12/23 download Created with Sketch. 211.47KB
IMM PEI provides constructive feedback for ph3 lung cancer trialPRICE SENSITIVE21/12/23 download Created with Sketch. 175.32KB
IMM Immutep receives A$2.6 million French R&D Tax IncentivePRICE SENSITIVE07/12/23 download Created with Sketch. 202.11KB
IMM Change of Director's Interest Notice - L Boyce23/11/23 download Created with Sketch. 132.26KB
IMM Change of Director's Interest Notice - R Howard23/11/23 download Created with Sketch. 128.56KB
IMM Notification regarding unquoted securities - IMM23/11/23 download Created with Sketch. 23.84KB
IMM Immutep Announces Site Expansion for INSIGHT-003 Trial22/11/23 download Created with Sketch. 272.31KB
IMM Proposed issue of securities - IMM22/11/23 download Created with Sketch. 24.98KB
IMM Immutep Completes Enrolment for TACTI-003 Phase IIb TrialPRICE SENSITIVE09/11/23 download Created with Sketch. 297.61KB
IMM Lead-in phase completed for ph2/3 trial in Breast CancerPRICE SENSITIVE06/11/23 download Created with Sketch. 280.55KB
IMM New Biomarker Data from TACTI-002 trial in 1st line NSCLCPRICE SENSITIVE03/11/23 download Created with Sketch. 296.42KB
IMM Immutep to Participate in November Investor Events02/11/23 download Created with Sketch. 214.57KB
IMM Immutep Quarterly Activities Report and Appendix 4CPRICE SENSITIVE31/10/23 download Created with Sketch. 694.24KB
IMM Annual Report filed on Form 20-F with SEC25/10/23 download Created with Sketch. 633.79KB
IMM Immutep receives Australian R&D Tax Incentive25/10/23 download Created with Sketch. 210.39KB
IMM Results of Meeting24/10/23 download Created with Sketch. 174.92KB
IMM Immutep AGM 2023 - CEO's Presentation24/10/23 download Created with Sketch. 3.7MB
IMM Immutep AGM 2023 - Chairman's Address24/10/23 download Created with Sketch. 232.73KB
IMM Immutep reports promising data from INSIGHT-003 trialPRICE SENSITIVE24/10/23 download Created with Sketch. 353.81KB
IMM Webcast slides for new Efti clinical data in 1st line NSCLCPRICE SENSITIVE23/10/23 download Created with Sketch. 4.6MB
IMM Excellent Overall Survival in Non-Small Cell Lung CancerPRICE SENSITIVE23/10/23 download Created with Sketch. 358.22KB
IMM Immutep announces publication of ESMO 2023 abstractsPRICE SENSITIVE16/10/23 download Created with Sketch. 311.9KB
IMM Change of Director's Interest Notice - Pete Meyers05/10/23 download Created with Sketch. 129.89KB
IMM Application for quotation of securities - IMM03/10/23 download Created with Sketch. 25.49KB
IMM Immutep announces acceptance of abstract for SITC 202303/10/23 download Created with Sketch. 239.64KB
IMM Notice of Annual General Meeting/Proxy Form22/09/23 download Created with Sketch. 628.1KB
IMM Appendix 4G and Corporate Governance Statement22/09/23 download Created with Sketch. 800.13KB
IMM Annual Report to shareholders22/09/23 download Created with Sketch. 1.17MB
IMM Commercial Scale Manufacturing of Efti for Clinical TrialsPRICE SENSITIVE21/09/23 download Created with Sketch. 271.75KB
IMM 2023 AGM & Key Dates08/09/23 download Created with Sketch. 195.98KB
IMM Immutep to Participate in September Investor Conferences06/09/23 download Created with Sketch. 210.44KB
IMM Appendix 4E & 2023 Full Year Statutory AccountsPRICE SENSITIVE30/08/23 download Created with Sketch. 2.45MB
IMM Immutep Investor Update18/08/23 download Created with Sketch. 699.16KB
IMM Immutep receives positive scientific advice from EMAPRICE SENSITIVE01/08/23 download Created with Sketch. 188.96KB
IMM Efti clinical data to be presented at ESMO Congress 202331/07/23 download Created with Sketch. 271.5KB
IMM Immutep Quarterly Activities Report and Appendix 4CPRICE SENSITIVE31/07/23 download Created with Sketch. 993.99KB
IMM 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma TrialPRICE SENSITIVE28/07/23 download Created with Sketch. 224KB
IMM Application for quotation of securities - IMM29/06/23 download Created with Sketch. 24.71KB
IMM US patent granted for Efti with PD-1 pathway inhibitorPRICE SENSITIVE27/06/23 download Created with Sketch. 214.05KB
IMM Immutep completes underwritten retail entitlement offerPRICE SENSITIVE27/06/23 download Created with Sketch. 225.06KB
IMM Immutep granted US patent for IMP761 agonist LAG-3 antibodyPRICE SENSITIVE20/06/23 download Created with Sketch. 212.09KB
IMM Change in substantial holding from IFL16/06/23 download Created with Sketch. 127.38KB
IMM Change in substantial holding13/06/23 download Created with Sketch. 281.56KB
IMM Change in substantial holding13/06/23 download Created with Sketch. 1.54MB
IMM Becoming a substantial holder09/06/23 download Created with Sketch. 213.18KB
IMM Cleansing Notice08/06/23 download Created with Sketch. 248.03KB
IMM Application for quotation of securities - IMM08/06/23 download Created with Sketch. 26.94KB
IMM Immutep letter to ineligible shareholders06/06/23 download Created with Sketch. 280.43KB
IMM Immutep retail entitlement offer booklet06/06/23 download Created with Sketch. 5.79MB
IMM Positive final data in 2nd line head and neck cancer at ASCO05/06/23 download Created with Sketch. 297.73KB
IMM Immutep completes institutional pro-rata offer & placementPRICE SENSITIVE02/06/23 download Created with Sketch. 247.12KB
IMM Change in substantial holding01/06/23 download Created with Sketch. 338.85KB
IMM Cleansing Notice31/05/23 download Created with Sketch. 242.45KB
IMM Proposed issue of securities - IMM31/05/23 download Created with Sketch. 40.13KB
IMM Immutep Capital Raising PresentationPRICE SENSITIVE31/05/23 download Created with Sketch. 4.15MB
IMM A$80 million fully underwritten equity raisingPRICE SENSITIVE31/05/23 download Created with Sketch. 301.15KB
IMM Trading HaltPRICE SENSITIVE31/05/23 download Created with Sketch. 291.28KB
IMM Charles River Laboratories to run IMP761 Toxicology StudyPRICE SENSITIVE29/05/23 download Created with Sketch. 217.16KB
IMM Publication of Abstracts for ASCO 2023 Annual MeetingPRICE SENSITIVE26/05/23 download Created with Sketch. 250.74KB
IMM 1st patient dosed in AIPAC-003 ph2/3 breast cancer trialPRICE SENSITIVE25/05/23 download Created with Sketch. 214.76KB
IMM Promising New Data in 1st line NSCLC from INSIGHT-003 TrialPRICE SENSITIVE24/05/23 download Created with Sketch. 213.71KB
IMM Excellent initial Overall Survival Benefit in 1st line NSCLCPRICE SENSITIVE17/05/23 download Created with Sketch. 232.58KB
IMM FDA supportive of Efti registrational trial in lung cancerPRICE SENSITIVE16/05/23 download Created with Sketch. 220.34KB
IMM Change of Director's Interest Notice - R Howard02/05/23 download Created with Sketch. 214.77KB
IMM Approval to start Efti & Bavencio trial in urothelial cancerPRICE SENSITIVE01/05/23 download Created with Sketch. 238.86KB
IMM Immutep Quarterly Activities Report and Appendix 4CPRICE SENSITIVE27/04/23 download Created with Sketch. 455.71KB
IMM Immutep to announce new TACTI-002 data at ASCO 2023PRICE SENSITIVE27/04/23 download Created with Sketch. 266.86KB
IMM Immutep appoints Dr Florian Vogl as Chief Medical Officer26/04/23 download Created with Sketch. 167.03KB
IMM Response to ASX Aware QueryPRICE SENSITIVE18/04/23 download Created with Sketch. 906.49KB
IMM Initiation of Phase 2 Trial for Efti in Soft Tissue SarcomaPRICE SENSITIVE17/04/23 download Created with Sketch. 245.57KB
IMM Notification of cessation of securities - IMM11/04/23 download Created with Sketch. 21.53KB
IMM Appendix 3Z - Lucy Turnbull11/04/23 download Created with Sketch. 205.54KB
IMM Appendix 3X - Lis Boyce11/04/23 download Created with Sketch. 167.62KB
IMM Immutep Announces Changes to the Board11/04/23 download Created with Sketch. 210.12KB
IMM Positive Final Data in 2nd Line Metastatic NSCLC PatientsPRICE SENSITIVE31/03/23 download Created with Sketch. 283.42KB
IMM Change in substantial holding31/03/23 download Created with Sketch. 1.52MB
IMM Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLCPRICE SENSITIVE30/03/23 download Created with Sketch. 251.07KB
IMM Abstract accepted for ESMO's European Lung Cancer Congress23/03/23 download Created with Sketch. 284.98KB
IMM Positive initial data in phase 2 Soft Tissue Sarcoma trial
02/05/24PRICE SENSITIVE download Created with Sketch. 200.6KB
IMM Immutep Quarterly Activities Report and Appendix 4C
29/04/24PRICE SENSITIVE download Created with Sketch. 499.37KB
IMM Positive preliminary topline results from TACTI-003 Cohort B
24/04/24PRICE SENSITIVE download Created with Sketch. 241.01KB
IMM CHDR to conduct first-in-human phase 1 trial of IMP761
18/04/24PRICE SENSITIVE download Created with Sketch. 299.16KB
IMM Positive Feedback received from Spanish Medicines Agency
17/04/24 download Created with Sketch. 173.58KB
IMM Ceasing to be a substantial holder
11/04/24 download Created with Sketch. 671.48KB
IMM Ceasing to be a substantial holder
08/03/24 download Created with Sketch. 42.52KB
IMM First Clinical Data announced from 90mg Dosing of Efti
05/03/24PRICE SENSITIVE download Created with Sketch. 253.51KB
IMM Half Yearly Report and Accounts
28/02/24PRICE SENSITIVE download Created with Sketch. 2.01MB
IMM Becoming a substantial holder
26/02/24 download Created with Sketch. 170.17KB
IMM Change in substantial holding
22/02/24 download Created with Sketch. 675.37KB
IMM Immutep Investor Update
21/02/24 download Created with Sketch. 1.43MB
IMM Change in substantial holding
20/02/24 download Created with Sketch. 88.53KB
IMM Becoming a substantial holder
15/02/24 download Created with Sketch. 90.89KB
IMM Ceasing to be a substantial holder
14/02/24 download Created with Sketch. 155.43KB
IMM Appendix 3X - Anne Anderson
14/02/24 download Created with Sketch. 169.25KB
IMM Appointment of Non-Executive Director
14/02/24 download Created with Sketch. 176.94KB
IMM Notification regarding unquoted securities - IMM
31/01/24 download Created with Sketch. 26.69KB
IMM Immutep Quarterly Activities Report and Appendix 4C
30/01/24PRICE SENSITIVE download Created with Sketch. 542.91KB
IMM Change in substantial holding
15/01/24 download Created with Sketch. 683.83KB
IMM Immutep Corporate Presentation
08/01/24 download Created with Sketch. 5.32MB
IMM First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial
04/01/24 download Created with Sketch. 176.39KB
IMM Change of Registered Office Address
22/12/23 download Created with Sketch. 211.47KB
IMM PEI provides constructive feedback for ph3 lung cancer trial
21/12/23PRICE SENSITIVE download Created with Sketch. 175.32KB
IMM Immutep receives A$2.6 million French R&D Tax Incentive
07/12/23PRICE SENSITIVE download Created with Sketch. 202.11KB
IMM Change of Director's Interest Notice - L Boyce
23/11/23 download Created with Sketch. 132.26KB
IMM Change of Director's Interest Notice - R Howard
23/11/23 download Created with Sketch. 128.56KB
IMM Notification regarding unquoted securities - IMM
23/11/23 download Created with Sketch. 23.84KB
IMM Immutep Announces Site Expansion for INSIGHT-003 Trial
22/11/23 download Created with Sketch. 272.31KB
IMM Proposed issue of securities - IMM
22/11/23 download Created with Sketch. 24.98KB
IMM Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
09/11/23PRICE SENSITIVE download Created with Sketch. 297.61KB
IMM Lead-in phase completed for ph2/3 trial in Breast Cancer
06/11/23PRICE SENSITIVE download Created with Sketch. 280.55KB
IMM New Biomarker Data from TACTI-002 trial in 1st line NSCLC
03/11/23PRICE SENSITIVE download Created with Sketch. 296.42KB
IMM Immutep to Participate in November Investor Events
02/11/23 download Created with Sketch. 214.57KB
IMM Immutep Quarterly Activities Report and Appendix 4C
31/10/23PRICE SENSITIVE download Created with Sketch. 694.24KB
IMM Annual Report filed on Form 20-F with SEC
25/10/23 download Created with Sketch. 633.79KB
IMM Immutep receives Australian R&D Tax Incentive
25/10/23 download Created with Sketch. 210.39KB
IMM Results of Meeting
24/10/23 download Created with Sketch. 174.92KB
IMM Immutep AGM 2023 - CEO's Presentation
24/10/23 download Created with Sketch. 3.7MB
IMM Immutep AGM 2023 - Chairman's Address
24/10/23 download Created with Sketch. 232.73KB
IMM Immutep reports promising data from INSIGHT-003 trial
24/10/23PRICE SENSITIVE download Created with Sketch. 353.81KB
IMM Webcast slides for new Efti clinical data in 1st line NSCLC
23/10/23PRICE SENSITIVE download Created with Sketch. 4.6MB
IMM Excellent Overall Survival in Non-Small Cell Lung Cancer
23/10/23PRICE SENSITIVE download Created with Sketch. 358.22KB
IMM Immutep announces publication of ESMO 2023 abstracts
16/10/23PRICE SENSITIVE download Created with Sketch. 311.9KB
IMM Change of Director's Interest Notice - Pete Meyers
05/10/23 download Created with Sketch. 129.89KB
IMM Application for quotation of securities - IMM
03/10/23 download Created with Sketch. 25.49KB
IMM Immutep announces acceptance of abstract for SITC 2023
03/10/23 download Created with Sketch. 239.64KB
IMM Notice of Annual General Meeting/Proxy Form
22/09/23 download Created with Sketch. 628.1KB
IMM Appendix 4G and Corporate Governance Statement
22/09/23 download Created with Sketch. 800.13KB
IMM Annual Report to shareholders
22/09/23 download Created with Sketch. 1.17MB
IMM Commercial Scale Manufacturing of Efti for Clinical Trials
21/09/23PRICE SENSITIVE download Created with Sketch. 271.75KB
IMM 2023 AGM & Key Dates
08/09/23 download Created with Sketch. 195.98KB
IMM Immutep to Participate in September Investor Conferences
06/09/23 download Created with Sketch. 210.44KB
IMM Appendix 4E & 2023 Full Year Statutory Accounts
30/08/23PRICE SENSITIVE download Created with Sketch. 2.45MB
IMM Immutep Investor Update
18/08/23 download Created with Sketch. 699.16KB
IMM Immutep receives positive scientific advice from EMA
01/08/23PRICE SENSITIVE download Created with Sketch. 188.96KB
IMM Efti clinical data to be presented at ESMO Congress 2023
31/07/23 download Created with Sketch. 271.5KB
IMM Immutep Quarterly Activities Report and Appendix 4C
31/07/23PRICE SENSITIVE download Created with Sketch. 993.99KB
IMM 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial
28/07/23PRICE SENSITIVE download Created with Sketch. 224KB
IMM Application for quotation of securities - IMM
29/06/23 download Created with Sketch. 24.71KB
IMM US patent granted for Efti with PD-1 pathway inhibitor
27/06/23PRICE SENSITIVE download Created with Sketch. 214.05KB
IMM Immutep completes underwritten retail entitlement offer
27/06/23PRICE SENSITIVE download Created with Sketch. 225.06KB
IMM Immutep granted US patent for IMP761 agonist LAG-3 antibody
20/06/23PRICE SENSITIVE download Created with Sketch. 212.09KB
IMM Change in substantial holding from IFL
16/06/23 download Created with Sketch. 127.38KB
IMM Change in substantial holding
13/06/23 download Created with Sketch. 281.56KB
IMM Change in substantial holding
13/06/23 download Created with Sketch. 1.54MB
IMM Becoming a substantial holder
09/06/23 download Created with Sketch. 213.18KB
IMM Cleansing Notice
08/06/23 download Created with Sketch. 248.03KB
IMM Application for quotation of securities - IMM
08/06/23 download Created with Sketch. 26.94KB
IMM Immutep letter to ineligible shareholders
06/06/23 download Created with Sketch. 280.43KB
IMM Immutep retail entitlement offer booklet
06/06/23 download Created with Sketch. 5.79MB
IMM Positive final data in 2nd line head and neck cancer at ASCO
05/06/23 download Created with Sketch. 297.73KB
IMM Immutep completes institutional pro-rata offer & placement
02/06/23PRICE SENSITIVE download Created with Sketch. 247.12KB
IMM Change in substantial holding
01/06/23 download Created with Sketch. 338.85KB
IMM Cleansing Notice
31/05/23 download Created with Sketch. 242.45KB
IMM Proposed issue of securities - IMM
31/05/23 download Created with Sketch. 40.13KB
IMM Immutep Capital Raising Presentation
31/05/23PRICE SENSITIVE download Created with Sketch. 4.15MB
IMM A$80 million fully underwritten equity raising
31/05/23PRICE SENSITIVE download Created with Sketch. 301.15KB
IMM Trading Halt
31/05/23PRICE SENSITIVE download Created with Sketch. 291.28KB
IMM Charles River Laboratories to run IMP761 Toxicology Study
29/05/23PRICE SENSITIVE download Created with Sketch. 217.16KB
IMM Publication of Abstracts for ASCO 2023 Annual Meeting
26/05/23PRICE SENSITIVE download Created with Sketch. 250.74KB
IMM 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial
25/05/23PRICE SENSITIVE download Created with Sketch. 214.76KB
IMM Promising New Data in 1st line NSCLC from INSIGHT-003 Trial
24/05/23PRICE SENSITIVE download Created with Sketch. 213.71KB
IMM Excellent initial Overall Survival Benefit in 1st line NSCLC
17/05/23PRICE SENSITIVE download Created with Sketch. 232.58KB
IMM FDA supportive of Efti registrational trial in lung cancer
16/05/23PRICE SENSITIVE download Created with Sketch. 220.34KB
IMM Change of Director's Interest Notice - R Howard
02/05/23 download Created with Sketch. 214.77KB
IMM Approval to start Efti & Bavencio trial in urothelial cancer
01/05/23PRICE SENSITIVE download Created with Sketch. 238.86KB
IMM Immutep Quarterly Activities Report and Appendix 4C
27/04/23PRICE SENSITIVE download Created with Sketch. 455.71KB
IMM Immutep to announce new TACTI-002 data at ASCO 2023
27/04/23PRICE SENSITIVE download Created with Sketch. 266.86KB
IMM Immutep appoints Dr Florian Vogl as Chief Medical Officer
26/04/23 download Created with Sketch. 167.03KB
IMM Response to ASX Aware Query
18/04/23PRICE SENSITIVE download Created with Sketch. 906.49KB
IMM Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
17/04/23PRICE SENSITIVE download Created with Sketch. 245.57KB
IMM Notification of cessation of securities - IMM
11/04/23 download Created with Sketch. 21.53KB
IMM Appendix 3Z - Lucy Turnbull
11/04/23 download Created with Sketch. 205.54KB
IMM Appendix 3X - Lis Boyce
11/04/23 download Created with Sketch. 167.62KB
IMM Immutep Announces Changes to the Board
11/04/23 download Created with Sketch. 210.12KB
IMM Positive Final Data in 2nd Line Metastatic NSCLC Patients
31/03/23PRICE SENSITIVE download Created with Sketch. 283.42KB
IMM Change in substantial holding
31/03/23 download Created with Sketch. 1.52MB
IMM Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
30/03/23PRICE SENSITIVE download Created with Sketch. 251.07KB
IMM Abstract accepted for ESMO's European Lung Cancer Congress
23/03/23 download Created with Sketch. 284.98KB
(20min delay)
Last
42.0¢
Change
0.000(0.00%)
Mkt cap ! $499.3M
Open High Low Value Volume
42.0¢ 43.0¢ 40.5¢ $1.108M 2.653M

Buyers (Bids)

No. Vol. Price($)
1 24000 41.5¢
 

Sellers (Offers)

Price($) Vol. No.
42.0¢ 101546 47
View Market Depth
Last trade - 16.10pm 02/05/2024 (20 minute delay) ?
Last
42.0¢
  Change
0.000 ( 0.90 %)
Open High Low Volume
43.0¢ 43.0¢ 41.0¢ 749406
Last updated 15.59pm 02/05/2024 ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.